More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Go back to More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026| BARNES GROUP, Inc. (NYSE: B) | Delayed: 36.99 -0.52 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.51 | 52 Week High | $44.27 | |||
| Open | $36.82 | 52 Week Low | $30.07 | |||
| Day High | $37.26 | P/E | 28.24 | |||
| Day Low | $36.42 | EPS | $1.31 | |||
| Volume | 5,057,073 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 21.28 -0.66 (3.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.94 | 52 Week High | $8.73 | |||
| Open | $21.33 | 52 Week Low | $2.86 | |||
| Day High | $21.94 | P/E | N/A | |||
| Day Low | $21.19 | EPS | $-3.82 | |||
| Volume | 174,627 | |||||
